Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.

The accepted patent application, No. 580712, specifically claims “multiple sequence-independent and length-independent nucleic acid constructs having one or more unlocked nucleobase analogs,” according to Marina. The constructs include RISC- and Dicer-length siRNAs, microRNA mimetics and antagonists, and single-stranded oligos.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.